Verici Dx Plc · LSE:VRCI
Verici Dx — H1 2021 Earnings Presentation
17 slides from Verici Dx's earnings presentation, Sep 13, 2021
Slide 1: Half-Year Results 2021
Half-Year Results 2021 Sara Barrington, CEO David Anderson, CFO Period ended 30 June 2021
Slide 2: Disclaimer
Disclaimer The information contained in this document has been prepared by Verici Dx plc (the ‘Group’ or ‘Company’). This document does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any shares in the Company nor shall it form the basis of or b
Slide 3: Overview
Overview - Immuno-diagnostics development company, initial focus on the kidney transplantation market - 5 – 10 million people die annually from kidney disease (WHO) compared with 1.8m from lung cancer (leading cancer related death) and about 300k are currently waiting for a transplant - Three initia
Slide 4: Experienced leadership for developing and commercialising kidney transplants assays
Experienced leadership for developing and commercialising kidney transplants assays Julian Baines Sir Ian Carruthers Non-executive Chairman Senior Independent EKF Diagnostics; Previously Non-executive Director BBI Chancellor UWE, Snr Director NHS Lorenzo Gallon Erik Lium Non-executive Director Non-e
Slide 5: Multinational Science Advisory Board of Key Opinion Leaders
Multinational Science Advisory Board of Key Opinion Leaders Lorenzo Gallon, MD (Chair) • Six past Presidents of major Tony Dorling, MD international transplant organizations Richard Formica, MD (AST, TTS, ASTS) Chris Larsen, MD, Dphil Roslyn Mannon, MD • Represent transplant centers Peter Nickerson,
Slide 6: Critical need for personalised diagnostic information
Critical need for personalised diagnostic information What is the risk of Is the graft being rejected rejection? or damaged? Current practice: Current practice: Broad Clinical Factors/Score Therapeutic Dilemma Standard of Care • Too general and • Misses 30% of all cases largely ignored No prognostic
Slide 7: Improved testing increases chances for graft survival
Improved testing increases chances for graft survival Pre-Transplant Prognostic Post-Transplant Diagnostic Patients now can be prescribed treatment at an appropriate level mRNA 23 gene Signature mRNA 17 gene Signature Advantages: Advantages: • Provides risk score for early acute • Specific real time
Slide 8: Initial total addressable market for lead products is about $700m p.a before growth
Initial total addressable market for 2 lead products is about $700m p.a before growth Pre-Transplant Evaluation Post-Transplant Follow-up Addressable market $285 million could triple should $428 million per annum supply issues be per annum addressed 11
Slide 9: H1 2021: Operational & financial highlights
H1 2021: Operational & financial highlights - Partnered with five leading US centres to collaborate on clinical validation trial for lead products, Clarava™ and Tuteva™ - Expanded Overview scope of licence agreement with Mount Sinai, in January 2021, to include an additional patent filing related to
Slide 10: Post-period end highlights
Post-period end highlights - Overview Obtained CLIA Certification of Registration for the Company’s newly established US clinical laboratory in Tennessee following launch of accelerated process, authorising the Company to initiate commercial operations as a diagnostic laboratory, a key milestone tow
Slide 11: Robust Clinical Pathway to revenues in two years
Robust Clinical Pathway to revenues in two years 2020 2021 2022 2023 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Clarava & Tuteva Utility Multi-center case validation Clinical Clinical validation studies Clarava & trials utility utility trials completed Protega Tuteva completed studies studies commence patient
Slide 12: Unaudited Financial Report
Appendix Unaudited Financial Report 12
Slide 13: Consolidated Income Statement
Consolidated Income Statement For the period ended 30 June 2021 Income Statement $’000 Adjusted EBITDA loss $’000 Admin expenses (2,708) Employee costs (764) Share based payments (128) Laboratory and development costs (1,044) Interest (3) Professional costs (455) Loss (2,839) Other costs (259) Adjus
Slide 14: Consolidated Balance Sheet
Consolidated Balance Sheet As of 30 June 2021 $’000 Intangible assets 1,884 Tangible assets 912 No development expenditure capitalized Cash 14,549 Other debtors – mainly prepayments Other debtors 426 Other liabilities – mainly clinical trial accruals Accounts payable (253) Other liabilities (324) To
Slide 15: Consolidated Cash Flow
Consolidated Cash Flow For the period ended 30 June 2021 $’000 Cash used by operations (2,788) Purchase of tangible assets (508) Foreign exchange – strength of £ v $ Addition to intangible assets (154) Cash runway to Q2 2023 Interest (3) Net cash outflow (3,453) Foreign exchange 251 Cash balance as
Slide 16: Verici Dx is poised to be at the forefront of kidney transplant diagnostics
Verici Dx is poised to be at the forefront of kidney transplant diagnostics Clearly differentiated Clinical Utility Key partnerships technology Direct measurement Patient and health economic Key influencers in of immune response outcomes are improved transplant facilitate a High clinical Therapeutic
Slide 17: Slide 17